Physician profile
Shobin Oommen
NPI 1205035383
$1,184.73
in general payments reported to CMS, 2019-2025
7 companies · $69.77 in 2025
The $69.77 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $396 · 2022: $570 · 2023: $28.74 · 2025: $69.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $675.49 | 2021-2023 | Aristada, Lybalvi |
| Acadia Pharmaceuticals INC | $214.03 | 2022 | |
| Avanir Pharmaceuticals, INC. | $120.79 | 2020 | |
| Neurocrine Biosciences, INC. | $104.65 | 2022 | |
| Collegium Pharmaceutical, INC. | $23.87 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $23.49 | 2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $22.41 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shobin Oommen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.